arrow
R

Ravit Geva

Tel Aviv Sourasky Medical Center
H指数:44
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

FAZ053的首次人体研究,FAZ053是一种抗程序性死亡配体1(anti-PD-L1)单克隆抗体,单独使用及与spartalizumab(抗PD-1)联用,用于治疗晚期恶性肿瘤患者

2025-06-010
PRE
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study

Nivolumab联合治疗晚期胃癌和胃食管交界癌患者: II期胃癌研究

2025-02-010
OAAI
Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

I期首次人体剂量递增研究的结果,该研究评估了第一类抗ILT2抗体SAR444881单药及联合pembrolizumab或cetuximab在晚期实体瘤患者中的疗效。

2024-09-010
PRE
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial (vol 42, pg 145, 2024)

CXCR2拮抗剂navarixin联合pembrolizumab治疗晚期实体瘤: 一项2期随机试验 (第42卷,145页,2024)

2024-05-200
OAAI
Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors
2024-04-050
PRE
Intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L/IL-23/IL-36γ in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment (TME) of patients with advanced solid tumors
2024-03-221
PRE
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

CXCR2拮抗剂navarixin联合pembrolizumab治疗晚期实体瘤: 一项2期随机试验

2024-02-0718
OAAI
Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity

无功能胰腺神经内分泌肿瘤 (nf-pnet) 中的血糖异常: 对一个未得到认可的实体的进一步见解

2023-09-012
OAAI
Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryption
2023-08-074
OAAI
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164

Pembrolizumab用于先前治疗的微卫星不稳定性高/错配修复缺陷的晚期结直肠癌: KEYNOTE-164的最终分析

2023-06-0127
PRE